Immunome Inc Cash Flow-to-Debt Ratio
Immunome Inc cash flow-to-debt ratio. Immunome Inc (IMNM) has a Cash Flow-to-Debt Ratio of -1.53x as of June 2026, meaning its operating cash flow of $-61.69 Million could theoretically repay -2% of its total liabilities ($40.30 Million) in one year. See Immunome Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Immunome Inc (2018–2025)
Cash flow-to-debt ratio of Immunome Inc from 2018 to 2025. Historical debt coverage capacity for Immunome Inc across 8 annual periods. Check Immunome Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Immunome Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Immunome Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Immunome Inc. For the full cash flow conversion analysis, see Immunome Inc (IMNM) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.91x | $-190.92 Million | $48.84 Million | ▼ -108.4% |
| 2024 | -1.88x | $-110.79 Million | $59.08 Million | ▼ -610.2% |
| 2023 | -0.26x | $-7.57 Million | $28.66 Million | ▲ +93.2% |
| 2022 | -3.88x | $-28.69 Million | $7.39 Million | ▼ -107.4% |
| 2021 | -1.87x | $-18.23 Million | $9.74 Million | ▲ +51.0% |
| 2020 | -3.82x | $-12.13 Million | $3.18 Million | ▼ -1517.3% |
| 2019 | -0.24x | $-9.60 Million | $40.69 Million | ▲ +5.5% |
| 2018 | -0.25x | $-7.41 Million | $29.65 Million | — |